VRCA — Verrica Pharmaceuticals Balance Sheet
0.000.00%
- $39.20m
- $61.95m
- $7.57m
- 20
- 22
- 38
- 14
Annual balance sheet for Verrica Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 65.5 | 70.4 | 34.3 | 69.5 | 46.3 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 0.487 | 4.42 | 0.077 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 67.7 | 74.3 | 39.1 | 77.5 | 51.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.94 | 5.5 | 5.33 | 3.62 | 2.58 |
| Other Long Term Assets | |||||
| Total Assets | 74.2 | 80.1 | 44.7 | 81.6 | 54.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 39.5 | 46.1 | 3.46 | 17 | 29 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 41.2 | 47.5 | 4.69 | 61.8 | 64 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 33 | 32.6 | 40 | 19.8 | -9.86 |
| Total Liabilities & Shareholders' Equity | 74.2 | 80.1 | 44.7 | 81.6 | 54.1 |
| Total Common Shares Outstanding |